ObjectiveTo evaluate the antitumor activity of the newly designed and synthesized myricetin derivative S2-1-5 against human hepatoma SMMC-7721 cells, so as to provide theoretical and experimental basis for the structural optimization of myricetin derivatives and the further development of anti-hepatoma drugs.

MethodsUsing myricetin as parent, S2-1-5 was synthesized by chemical reactions, its structure and quantitative analysis were carried out by nuclear magnetic resonance (NMR) and high resolution mass spectrometry (HRMS), and then its anti-tumor activity was verified: SMMC-7721 cells were treated with different concentrations of S2-1-5 and positive control drug gemcitabine, and DMSO was used as negative control.The proliferation inhibition of S2-1-5 on SMMC-7721 cells was detected by MTT assay and morphological observation, and the migration ability of SMMC-7721 cells was detected by scrape assay.The cell cycle and apoptosis of SMMC-7721 were detected by flow cytometry.

ResultsThe molecular structure of 2- fluorobenzyl 4- ((3- ((5, 7- dimethoxy -4- oxo -2-(3, 4, 5- trimethoxy phenyl)-4H- chromene -3- yl) oxy) propyl) (methyl) amino) piperidine -1- dithiocarboxylic acid (S2-1-5) was determined by NMR and HRMS.Its chemical formula was C₃₇H₄₃FN₂O₈S₂.The antitumor activity experiment of S2-1-5 showed that: Compared with the control group, the inhibition activity of S2-1-5 was higher at different concentrations, and the differences were significant; S2-1-5 could inhibit the migration of SMMC-7721 cells (P < 0.05).S2-1-5 inhibited the cell cycle of SMMC-7721 cells in S phase (P < 0.05);S2-1-5 could induce apoptosis of SMMC-7721 cells (P < 0.01).

ConclusionsS2-1-5 can inhibit the proliferation and migration of SMMC-7721 cells and induce cell cycle arrest and apoptosis to exert its antitumor effect in vitro.